Edition:
United States

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

1.27USD
15 Dec 2017
Change (% chg)

$0.07 (+5.83%)
Prev Close
$1.20
Open
$1.20
Day's High
$1.29
Day's Low
$1.20
Volume
49,578
Avg. Vol
28,758
52-wk High
$3.89
52-wk Low
$0.90

Latest Key Developments (Source: Significant Developments)

Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago
Tuesday, 14 Nov 2017 08:00am EST 

Nov 14 (Reuters) - Eyegate Pharmaceuticals Inc :Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update.Eyegate Pharmaceuticals Inc - ‍net loss in Q3 of 2017 was $4.1 million, compared with $3.4 million in Q3 of 2016​.  Full Article

EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery
Wednesday, 8 Nov 2017 08:30am EST 

Nov 8 (Reuters) - EyeGate Pharmaceuticals Inc :EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery.Eyegate Pharmaceuticals Inc - ‍topline data is expected to be released in Q1 of 2018 for phase 2b clinical trial of EGP-437 for cataract surgery​.  Full Article

Eyegate Pharmaceuticals Q2 revenue $148,000
Monday, 7 Aug 2017 07:30am EDT 

Aug 7 (Reuters) - Eyegate Pharmaceuticals Inc :Eyegate Pharmaceuticals reports second quarter 2017 financial results and provides business update.Q2 revenue $148,000 versus $235,000.Q2 revenue view $1.5 million -- Thomson Reuters I/B/E/S.Eyegate Pharmaceuticals Inc - ‍net loss for Q2 of 2017 was $3.3 million, compared with $3.8 million in Q2 of 2016​.Eyegate Pharmaceuticals Inc - cash and cash equivalents as of June 30, 2017 totaled $11.8 million, compared with $3.6 million as of December 31, 2016.  Full Article

Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc
Monday, 19 Jun 2017 05:10pm EDT 

June 19 (Reuters) - Armistice Capital LLC : :Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc, as of June 9, 2017 .  Full Article

Innoven Partenaires reports a 9.5 pct stake in Eyegate Pharmaceuticals
Friday, 16 Jun 2017 07:19am EDT 

June 16 (Reuters) - Innoven Partenaires S.A.::Innoven Partenaires S.A. reports a 9.5 percent stake in Eyegate Pharmaceuticals Inc as of June 14 - SEC filing.Innoven Partenaires S.A. had previously reported a 24.2 percent stake in Eyegate Pharmaceuticals Inc as of Feb 19, 2015.  Full Article

Empery Asset Management reports 9.22 pct passive stake in Eyegate Pharmaceuticals
Wednesday, 14 Jun 2017 02:29pm EDT 

June 14 (Reuters) - Empery Asset Management LP::Empery Asset Management LP reports a 9.22 percent passive stake in Eyegate Pharmaceuticals Inc as of June 9, 2017 - SEC filing.  Full Article

EyeGate receives milestone payment from Valeant
Monday, 22 May 2017 07:30am EDT 

May 22 (Reuters) - Eyegate Pharmaceuticals Inc : :EyeGate receives milestone payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients.EyeGate Pharmaceuticals Inc - granted Valeant exclusive, worldwide commercial and manufacturing rights to co's EyeGate II delivery system and EGP-437 combination product.EyeGate Pharmaceuticals - co is eligible to receive developmental and sales-based milestones totaling up to about $99.0 million, royalties on valeant's net sales of product.  Full Article

Eyegate Pharmaceuticals reports net loss of $2.9 million
Monday, 8 May 2017 08:30am EDT 

May 8 (Reuters) - Eyegate Pharmaceuticals Inc : :Eyegate Pharmaceuticals reports first quarter 2017 financial results and provides business update.Q1 revenue $190,000.Eyegate Pharmaceuticals Inc - cash and cash equivalents as of March 31, 2017 totaled $5.4 million, compared with $3.6 million as of December 31, 2016.Eyegate Pharmaceuticals Inc - net loss for three months ended March 31, 2017 was $2.9 million, compared with $2.4 million in Q1 of 2016.  Full Article

Eyegate Pharmaceuticals sees secondary offering of of 5.3 mln shares
Friday, 5 May 2017 04:33pm EDT 

May 5 (Reuters) - Eyegate Pharmaceuticals Inc :Sees secondary offering of its common stock of 5.3 million shares - sec filing.  Full Article

Eyegate files investigational device exemption for pilot study of ocular bandage gel
Thursday, 4 May 2017 07:30am EDT 

May 4 (Reuters) - Eyegate Pharmaceuticals Inc :Eyegate submits investigational device exemption (ide) filing for second pilot study of ocular bandage gel.Eyegate pharmaceuticals inc - review process is expected to take a minimum of 30 days.  Full Article

BRIEF-Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago

* Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update